Pune, Maharashtra, India:
Emcure Pharmaceuticals Ltd., among the top 15 largest pharmaceutical companies in India, announced the launch of ‘Uncondition Yourself’ – an initiative dedicated towards women’s well-being. The campaign launched on the occasion of ‘World Health Day’ will seek to identify and address the prevalent notions and misconceptions about women’s health and well-being from the cultural and social context in India. In the first phase, the campaign aims to put forth the challenges and connect with relevant influencers to initiate a step towards building a supportive ecosystem for women in the workforce. The campaign will involve on-ground engagement and online activities at a national level.
Speaking on the occasion, Ms. Namita Thapar, Executive Director, Emcure Pharmaceuticals, said, “Despite the economic advances we have made, even today, issues related to women’s health are associated with irrational taboos. These lead to stigmatization and more worryingly holding back among women about their health issues. Through the ‘Uncondition Yourself’ initiative, we hope to bring to light important health issues India’s significant women workforce face, and to educate them to make informed choices in their day-to-day actions.”
The campaign is an outcome of an online talk show ‘Uncondition yourself with Namita’ featuring candid heart to heart conversations on women’s health issues, giving accurate information and dispelling various myths. This programme received a tremendous response which encouraged the company to launch its ‘Uncondition Yourself’ initiative to engage with a wider audience.
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd. (EPL) is one of India’s largest pharmaceutical players headquartered in Pune with a global footprint. Driven by technology and innovation, the company’s mission has been to develop and deliver Effective Medicines to Cure patients, enabling them to lead healthier lives. Established in 1981, the firm was founded by Mr. Satish Mehta who spotted an opportunity in contract manufacturing pharmaceuticals for MNCs. The company is 12th largest pharma player in India by market share. It is also a market leader in cardiac, gynaecology, blood-related and HIV antiviral therapy areas. It is also developing India’s first mRNA vaccine for the novel coronavirus using its in-house built platform.
Emcure develops and sells a wide range of branded and generic formulations, API and biotechnology products in over 70 markets including India, Europe, Canada, Russia and nations across Latin America and the Middle-East through a strong global network of 19 subsidiaries. The company’s diversified portfolio of offerings caters to pain & analgesics, vitamins, minerals and nutrients, anti-infectives, diabetes, and neuroscience segments. Emcure pharmaceuticals products’ are predominantly aimed at chronic therapy. Emcure has 13 manufacturing sites, 5 research centres, over 10,000 professionals working globally. Its state-of-the-art R&D centres in India are recognized by the Department of Scientific & Industrial Research (DSIR).
To know more about Emcure, please visit: https://www.emcure.com/
Follow us on LinkedIn: https://www.linkedin.com/company/emcure-pharmaceuticals-limited/
Click here for Media Contact Details
Aasiya Shaikh, Adfactors PR, +91-9833503994
Syed Talal, Adfactors PR, +91-9987619679
Submit your press release